XTLB
XTL Biopharmaceuticals
XTLB
XTLB
5 hedge funds and large institutions have $194K invested in XTL Biopharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
$75K |
| 2 |
2
Citadel Advisors
Miami,
Florida
|
$33K |
| 3 |
3
Morgan Stanley
New York
|
$37K |
Top Sellers
| 1 |
1
Bank of America
Charlotte,
North Carolina
|
$0 |
| 2 |
2
UBS Group
Zurich,
Switzerland
|
$1K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $75K | 40,679 | +40,679 | New |
|
2
Invesco
Atlanta,
Georgia
| $48K | 25,961 | – | – |
|
|
3
Morgan Stanley
New York
| $37K | 20,161 | +4,300 | +27% |
|
|
4
Citadel Advisors
Miami,
Florida
| $33K | 17,312 | +17,312 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $1K | 692 | -437 | -39% |
|
|
6
Bank of America
Charlotte,
North Carolina
| – | – | -1,000 | Closed |
|